Progestin and breast cancer risk: a systematic review Marsha SamsonNancy PorterSusan E. Steck Review 23 December 2015 Pages: 3 - 12
Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer M. T. BranhamE. CampoyM. Roqué Preclinical study 27 November 2015 Pages: 13 - 23
Clinical utility of reverse phase protein array for molecular classification of breast cancer Ola H. NegmAbir A. MuftahAndrew R. Green Preclinical study 09 December 2015 Pages: 25 - 35
184AA3: a xenograft model of ER+ breast adenocarcinoma William C. HinesIrene KuhnMina J. Bissell Preclinical study 12 December 2015 Pages: 37 - 52
Survivin contributes to DNA repair by homologous recombination in breast cancer cells Eloïse VéquaudGrégoire DesplanquesSophie Barillé-Nion Preclinical Study Open access 18 December 2015 Pages: 53 - 63
Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets Saki NakagawaYasuhiro MikiHironobu Sasano Preclinical study 29 December 2015 Pages: 65 - 75
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer C. JacobsI. KuchukM. Clemons Clinical trial 07 December 2015 Pages: 77 - 84
Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype Werner SchrothS. WinterP. Fritz Clinical Trial 09 December 2015 Pages: 85 - 97
Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial Akiko HanaiHiroshi IshiguroTadao Tsuboyama Clinical Trial Open access 09 December 2015 Pages: 99 - 107
Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer Thomas KolbenD. AugustinR. Wuerstlein Clinical Trial 07 December 2015 Pages: 109 - 115
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial Lucia Del MastroAlessia LevaggiPaolo Bruzzi Clinical trial 10 December 2015 Pages: 117 - 126
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience Otto Metzger-FilhoEvandro de AzambujaHREA Study Team Clinical trial 26 December 2015 Pages: 127 - 132
Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel Tamar Yablonski-PeretzShani Paluch-ShimonEitan Friedman Clinical Trial 19 December 2015 Pages: 133 - 138
Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients Diana H. LiangJoe E. EnsorAngel A. Rodriguez Epidemiology 14 December 2015 Pages: 139 - 149
The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom Nina SchimdtLouis JacobPeyman Hadji Epidemiology 19 December 2015 Pages: 151 - 157
Metastatic breast cancer patients: attitudes toward tissue donation for rapid autopsy Tala AchkarJohn WilsonShannon Puhalla Epidemiology 24 December 2015 Pages: 159 - 164
Rates of BRCA1/2 mutation testing among young survivors of breast cancer Kenneth L. KehlChan ShenSharon H. Giordano Epidemiology 26 December 2015 Pages: 165 - 173
The relationship between local recurrence and death in early-stage breast cancer Victoria SopikSharon Nofech-MozesSteven A. Narod Epidemiology 28 December 2015 Pages: 175 - 185
Factors associated with radiation therapy incompletion for patients with early-stage breast cancer Rachel A. FreedmanStacey A. FedewaHelmneh M. Sineshaw Brief Report 18 December 2015 Pages: 187 - 199
The therapy with negative pressure as a valid device to treat chronic breast infections Tommaso FogacciFederico CattinDomenico Samorani Letter to the Editor 25 November 2015 Pages: 201 - 202
